Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications

The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials

(2023) Egidio Imbalzano et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine

(2023) Mihaela Simona Popoviciu et al.   Journal of Personalized Medicine

PCSK9 participates in oxidized‐low density lipoprotein‐induced myocardial injury through mitochondrial oxidative stress and Drp1‐mediated mitochondrial fission

(2022) Xuan Li et al.   Clinical and Translational Medicine

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population

(2022) Yiming Wu et al.   Frontiers in Endocrinology

Insight into the Evolving Role of PCSK9

(2022) Mateusz Maligłówka et al.   Metabolites

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

(2022) Xing Wang et al.   Cardiovascular Diabetology

Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis

(2022) Algerta Marku et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

PCSK9: A emerging participant in heart failure

(2022) Qian Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis

(2022) Ni Kong et al.   Annals of Translational Medicine

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes

(2021) Susanne Rohrbach et al.   Frontiers in Physiology

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

(2021) Aureli Luquero et al.   Frontiers in Cardiovascular Medicine

PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction

(2021) Lorenzo Da Dalt et al.   EUROPEAN HEART JOURNAL

Diabetes insipidus

(2021) Mirjam Christ-Crain et al.   PRESSE MEDICALE

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

(2020) Yi Tan et al.   Nature Reviews Cardiology

A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α

(2020) Xuelei Wang et al.   EBioMedicine

The Role of Bone Morphogenetic Protein 7 (BMP-7) in Inflammation in Heart Diseases

(2020) Chandrakala Aluganti Narasimhulu et al.   Cells

Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

(2020) Ying Tang et al.   Cardiovascular Diabetology

The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion

(2020) Shi-jun Deng et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

An Update on the Role of PCSK9 in Atherosclerosis

(2020) Ece Yurtseven et al.   Journal of Atherosclerosis and Thrombosis

PCSK9 and atherosclerosis: Looking beyond LDL regulation

(2020) Rosetta Ragusa et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease

(2019) Davide Di Fusco et al.   Frontiers in Pharmacology

Cardiomyopathy in obesity, insulin resistance or diabetes

(2019) Michinari Nakamura et al.   JOURNAL OF PHYSIOLOGY-LONDON

Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial

(2019) Alberto J. Lorenzatti et al.   DIABETES OBESITY & METABOLISM

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

(2019) Oliver Schnell et al.   Cardiovascular Diabetology

Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte

(2019) Tiziana Filardi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment

(2019) Tatsuhiko Urakami   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Targeting PCSK9: Implications for basic science and upcoming challenges

(2019) Toshiyuki Nishikido et al.   BRITISH JOURNAL OF PHARMACOLOGY

WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition

(2019) Pouya Saeedi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects

(2019) Siripong Palee et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Mitochondrial connexin 43 in sex-dependent myocardial responses and estrogen-mediated cardiac protection following acute ischemia/reperfusion injury

(2019) Meijing Wang et al.   BASIC RESEARCH IN CARDIOLOGY

Mechanisms and regulation of cholesterol homeostasis

(2019) Jie Luo et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy

(2018) Maura Knapp et al.   ACTA PHARMACOLOGICA SINICA

PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions

(2018) Mika Hilvo et al.   ATHEROSCLEROSIS

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy

(2018) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

PCSK9

(2018) Michael D. Shapiro et al.   CIRCULATION RESEARCH

Diabetic Cardiomyopathy

(2018) Guanghong Jia et al.   CIRCULATION RESEARCH

PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?

(2018) Xue-qin Bai et al.   CLINICA CHIMICA ACTA

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

(2018) Lorenzo Da Dalt et al.   EUROPEAN HEART JOURNAL

PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque

(2018) A. Liu et al.   JOURNAL OF INTERNAL MEDICINE

The Evolving Future of PCSK9 Inhibitors

(2018) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

(2018) Wieneke Dijk et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

PCSK9 induces a pro-inflammatory response in macrophages

(2018) Chiara Ricci et al.   Scientific Reports

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review

(2018) Yehuda Handelsman et al.   Journal of the American Heart Association

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9

(2018) Brian T Emmer et al.   eLife

The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine

(2018) Xueling Ma et al.   Frontiers in Pharmacology

Of mice and men: models and mechanisms of diabetic cardiomyopathy

(2018) Christian Riehle et al.   BASIC RESEARCH IN CARDIOLOGY

Small molecules as inhibitors of PCSK9: Current status and future challenges

(2018) Shengtao Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women

(2017) Amy E. Levenson et al.   PEDIATRIC DIABETES

On type 1 diabetes mellitus pathogenesis

(2017) Stavroula A Paschou et al.   Endocrine Connections

PCSK9 signaling pathways and their potential importance in clinical practice

(2017) Michał Wiciński et al.   EPMA Journal

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

(2016) Yajnavalka Banerjee et al.   ATHEROSCLEROSIS

Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism

(2016) Blake J. Cochran et al.   DIABETES

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

(2016) Helen M. Colhoun et al.   EUROPEAN HEART JOURNAL

Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity

(2016) Ying Du et al.   Journal of Translational Medicine

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance

(2015) Annie Demers et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance

(2015) Ji Miao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cross-talk between LOX-1 and PCSK9 in vascular tissues

(2015) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

(2015) Nathalie Bergeron et al.   CIRCULATION

Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients

(2015) Ymène Nekaies et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

PCSK9 inhibition to reduce cardiovascular disease risk

(2015) Hagai Tavori et al.   Current Opinion in Endocrinology Diabetes and Obesity

BMP-7 attenuates adverse cardiac remodeling mediated through M2 macrophages in prediabetic cardiomyopathy

(2014) Princess Urbina et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Protein Sorting at the trans-Golgi Network

(2014) Yusong Guo et al.   Annual Review of Cell and Developmental Biology

PCSK9: From discovery to therapeutic applications

(2014) Michel Farnier   Archives of Cardiovascular Diseases

The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion

(2014) Camilla Gustafsen et al.   Cell Metabolism

Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

(2014) Qiurong Ding et al.   CIRCULATION RESEARCH

Mechanism linking diabetes mellitus and obesity

(2014) Abdullah Algoblan et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The Emerging Global Epidemic of Type 1 Diabetes

(2013) Jaakko Tuomilehto   Current Diabetes Reports

Mechanisms of Diabetic Complications

(2013) Josephine M. Forbes et al.   PHYSIOLOGICAL REVIEWS

Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy

(2013) Marina Bayeva et al.   Journal of the American Heart Association

Insulin Resistance: Metabolic Mechanisms and Consequences in the Heart

(2012) E. Dale Abel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Diabetic Complications: Current Challenges and Opportunities

(2012) Helen D. Nickerson et al.   Journal of Cardiovascular Translational Research

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study

(2011) M.C.G.J. Brouwers et al.   ATHEROSCLEROSIS

Clinical aspects of PCSK9

(2011) Bertrand Cariou et al.   ATHEROSCLEROSIS

LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications

(2011) Meiling Yan et al.   CARDIOVASCULAR DRUGS AND THERAPY

Induced Pluripotent Stem (iPS) Cells Inhibit Apoptosis and Fibrosis in Streptozotocin-Induced Diabetic Rats

(2011) Sarah Neel et al.   MOLECULAR PHARMACEUTICS

Stem cells in the diabetic infarcted heart

(2010) Carley E. Glass et al.   HEART FAILURE REVIEWS

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells

(2010) Hong Lan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Adnectins: engineered target-binding protein therapeutics

(2010) D. Lipovsek   PROTEIN ENGINEERING DESIGN & SELECTION

Diagnosis and Classification of Diabetes Mellitus

(2009)   DIABETES CARE

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities

(2009) Majambu Mbikay et al.   FEBS LETTERS

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

(2009) S. A. Mousavi et al.   JOURNAL OF INTERNAL MEDICINE

Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options

(2008) Ashish Aneja et al.   AMERICAN JOURNAL OF MEDICINE

Errata.PCSK9 function and physiology: Fig. 1.

(2008) Andrew S. Peterson et al.   JOURNAL OF LIPID RESEARCH